Navigation Links
Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
Date:12/10/2007

Conference Call Scheduled for 4:00 p.m. Eastern Time to Review Clinical Trial Results for SNS-595 and Non-clinical Data for SNS-032 Presented at

the ASH Meeting

ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company developing novel anticancer therapeutics, presented positive results for SNS-595 in relapsed or refractory acute leukemia patients in an oral session by Jeffrey Lancet, M.D, Assistant Professor, Division of Hematologic Malignancies at the H. Lee Moffitt Cancer Center & Research Institute, at the 49th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, Georgia. In a Phase 1 clinical trial, SNS-595 was generally well tolerated with anti-leukemic clinical activity when administered either once- or twice-weekly at biologically active doses.

In addition, non-clinical data showing that SNS-032 induces apoptosis in chronic lymphocytic leukemia (CLL) cells are being presented by William Plunkett, Ph.D., Professor and Chief, Section of Molecular and Cellular Oncology at the University of Texas M. D. Anderson, in a poster session. SNS-032 is currently in a Phase 1 clinical trial in patients with CLL or multiple myeloma.

Sunesis management will host a conference call today at 4:00 p.m. Eastern time to review the SNS-595 and SNS-032 data presented at the ASH meeting. Drs. Lancet and Plunkett will join management on the call.

Oral Presentation: A Phase 1b Open-Label Study of the Novel DNA Replication Inhibitor SNS-595 in Refractory Acute Leukemia (Abstract #442)

SNS-595, a first-in-class naphthyridine analog that intercalates DNA and poisons topoisomerase II causing selective DNA
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Thousand of GranuFlo lawsuits ( http://www.granuflolawsuit2014.com/ ... GranuFlo and NaturaLyte dialysis concentrates continue to move forward ... Court, District of Massachusetts, Bernstein Liebhard LLP reports. According ... remanded a case filed by the state of Louisiana ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
(Date:1/22/2015)... 22, 2015 IsoComforter, Inc. has introduced the ... patented IsoTube design to treat specific body parts and muscle ... progressive and easy to use patented cold therapy machine with ... related orthopedic and muscle injuries. IsoComforter has become the ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
(Date:1/22/2015)... 2015 Step into a macabre world ... Museum of Virginia. Wicked Plants, the Museum’s latest featured ... 75 poisonous, carnivorous and diabolical plants inside of a ... uncover the biochemical, physical and neurological processes between botanicals ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Wicked Plants are taking over the Science Museum of Virginia 2
... WASHINGTON, DC, March 7, 2011 The 2011 Sleep in America ... use of communications technology in the hour before bed. It also ... they say they need and are searching for ways to cope. ... week. , The poll found that 43% of Americans between the ...
... For years brain scientists have puzzled over the shadowy role ... present in the brain following an epileptic seizure, but without ... damage that follows a seizure or protect the brain from ... squarely on the side of good: It seems to protect ...
... new gene sites associated with the risk of coronary ... studies. Several of the novel sites discovered in ... Genetics, do not appear to relate to known risk ... "We now have identifed 23 specific genetic ,letters, ...
... symposium, the Society of Surgical Oncology will present the 43rd ... Barrington Hills, IL, for her deep commitment and long-term efforts ... patients get the information they need to make wise decisions ... March 5, at the Society,s 64th annual meeting in San ...
... in your exercise therapy could significantly improve your function ... the March print issue of Stroke: Journal of ... adding family-assisted exercise therapy to routine physical therapy after ... to perform daily living activities. It also lowered the ...
... (HealthDay News) -- Breast cancer survivors may be at increased risk ... chemotherapy and endocrine therapy, a new study suggests. Researchers looked ... of them had experienced a fall in the year before the ... the six-month study period. Those rates are much higher than ...
Cached Medicine News:Health News:Sleepy connected Americans 2Health News:Sleepy connected Americans 3Health News:Sleepy connected Americans 4Health News:Sleepy connected Americans 5Health News:Sleepy connected Americans 6Health News:New role for an old molecule: protecting the brain from epileptic seizures 2Health News:International collaborative identifies 13 new heart-disease-associated gene sites 2Health News:Cancer surgery society presents top honor to Kimberly Duchossois 2Health News:Stroke patients benefit from family involvement in exercise therapy 2Health News:Chemo May Raise Risk of Falls in Breast Cancer Survivors 2
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... , Jan. 22, 2015 Increasing sophistication among ... consolidation of localization purchasing in 2015, says Moravia ... to a recent study by market research firm Common ... single-source solution for their translation and localization needs. "From ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the ... today announced that it has filed its Form 10-Q for ... Securities and Exchange Commission. The Company provided an update on ... Year-to-date shipment volumes increased 93% compared to the ...
... 2011 China Nuvo Solar Energy, Inc. (OTCQB: CNUV) ... its previously announced stocking distributors, OptiMedical Corp. ("OptiMedical") is ... order and as a result has revised its forecast ... end of 2012. Additionally, the Company is negotiating with ...
Cached Medicine Technology:InspireMD Provides Mid-Year Strategic Update 2InspireMD Provides Mid-Year Strategic Update 3InspireMD Provides Mid-Year Strategic Update 4InspireMD Provides Mid-Year Strategic Update 5InspireMD Provides Mid-Year Strategic Update 6InspireMD Provides Mid-Year Strategic Update 7China Nuvo Solar Target Acquisition SurgLine Updates OptiMedical Corp.'s Sales Forecast in Excess of $10,000,000 2
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Irrigating nucleus chopper, tip angled 30 to side wedge shaped inferior edge with blunt tip and front notch for engaging iris end opening, 19 gauge. For use in the right hand....
Irrigating nucleus chopper, 0.6 mm dual sideports, 20 gauge. For the right handed surgeon....
Phaco chopper, a combination of a Sinskey hook and a pointed "quick chop" tip....
Medicine Products: